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Abstract
Objectives—In 2006, Medicare Part D transitioned prescription drug coverage for dual-eligible
nursing home residents from Medicaid to Medicare and randomly assigned them to Part D
prescription drug plans (PDPs). Because PDPs may differ in coverage, residents’ assigned plans
may be relatively more or less restrictive for drugs they take. Taking advantage of the fact that
randomization mitigates potential selection bias common in observational studies, this study seeks
to assess the impact of PDP coverageon resident outcomes for three medication classes –
antidepressants, antipsychotics, and cholinesterase inhibitors.
Design, Setting, Participants—Using Medicare claims, Minimum Data Set assessments,
pharmacy claims, and PDP formulary information, we estimate the impact of coverage restrictions
– including non-coverage and coverage with restrictions – on the following outcomes for dual-
eligible nursing home residents randomized to PDPs in 2006–2008: depression; hallucinations/
delusions; aggressive behaviors; cognitive performance; and activities of daily living. We further
adjust for baseline health status to address any residual imbalances in the comparison groups.
Results—Across 5 outcomes in each of three medication classes of interest, PDP coverage
restrictions impacted one resident health outcome: for cholinesterase inhibitor users, coverage
restrictions were associated with a 0.04 point lower depression rating score relative to residents
facing no restrictions. However, this result was not statistically significant after adjusting for
multiple comparisons.
Conclusion—Our findings suggest that exogenous changes in coverage for three commonly-
used medication classes had no detectable impact on nursing home resident health outcomes in
2006–2008. There are several possible explanations for this lack of association, including the role
of policy protections for dual-eligible nursing home residents and the possibility that suitable
clinical alternatives were identified or previously used medications offered little clinical benefit.
Keywords
Medicare Part D; coverage restrictions; nursing home
INTRODUCTION
In 2006, Medicare Part D transitioned prescription drug coverage for dual-eligible nursing
home residents from Medicaid to Medicare and began randomly assigning these residents to
Part D prescription drug plans (PDPs). Because PDPs differ in coverage restrictions,
residents’ assigned plans may be relatively more or less generous for the drugs they are
currently taking. Although previous studies have highlighted concerns related to the
transition of nursing home residents to Part D, (1–4) none has yet analyzed the impact of
PDP coverage restrictions on related resident health and functional outcomes.
Earlier studies examining the link between drug benefit coverage and medication use outside
of the nursing home Part D setting typically measured the relative generosity of coverage in
Stevenson et al. Page 2






















one of two ways: 1) the amount paid by the enrollee out of pocket;(5, 6) or 2) the share of
total drug expenditures paid by the enrollee out of pocket.(7, 8) Because dual-eligible
nursing home residents face no cost sharing under Part D, these approaches are
inappropriate for this context. Instead, a PDP formulary coverage measure for this
population must incorporate information on formulary coverage and utilization
management, including prior authorization and step therapy requirements, for medications
that residents take.
Among drugs used commonly by dual-eligible nursing home residents, who account for the
majority of residents nationwide, studies have documented variation across PDPs with
respect to benefit restrictions like formulary coverage, prior authorization, and step therapy
requirements. (1, 9) Based on their early experience with Part D, nursing home and long-
term care pharmacy (LTCP) stakeholders noted access challenges under Part D for a subset
of drugs, including Alzheimer’s drugs, selected brand antidepressants and atypical
antipsychotics, as well as alternate medication formulations (e.g., injectable, inhalation,
topical, and infusion solutions).(1) Examination of one large LTCP’s rejected claims
revealed a number of medications with a high volume of claims rejections, including the
products Lexapro, Aricept, Fentanyl, Seroquel, Risperdal, Namenda, and Procrit.(10, 11) To
date, the clinical impact of these coverage features has been unclear.
The randomization of dual-eligibles to PDPs offers an opportunity that potentially allows for
causal estimation of the impact of medication coverage restrictions on outcomes. Combining
multiple sources of data for approximately two-thirds of dual-eligible nursing home
residents in the U.S., we build in this paper on previous work examining the impact of PDP
coverage on the use of several medication classes commonly prescribed to nursing home
residents.(4) Following randomization into Part D, only a small portion of residents faced
non-coverage or utilization management requirements for drugs they were using at the time,
when evaluated at the molecule level (i.e., brand and generic formulations of a molecule
were treated as the same medication). Nonetheless, residents facing such restrictions were
more likely to change medications within the class and have usage gaps. Although the study
did not examine class- or condition-specific health outcomes, it did not find any statistically-
significant differences in overall hospitalization or death rates between residents with less
versus more restrictive medication coverage.
This paper analyzes the impact of PDP coverage on cognitive, behavioral, and functional
outcomes in three therapeutic classes: antidepressants, used to treat clinical depression and
other conditions; antipsychotics, used to treat schizophrenia and other psychotic disorders;
and cholinesterase inhibitors, used to treat symptoms of Alzheimer’s disease and related
neurological conditions. Each of these classes is commonly used by nursing home residents
and shares a set of relevant health status outcomes. Two classes – antidepressants and
antipsychotics – are currently “protected” under Part D, meaning PDPs must cover at least
one formulation of every drug in the class. The third – cholinesterase inhibitors – is not a
protected class; plans are required to cover only one drug in the class. For both protected and
non-protected classes, plans are permitted to use utilization management tools like prior
authorization and step therapy requirements to influence medication use. Our hypothesis
was that residents who face relatively restrictive coverage of their medications after
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enrollment in their new plan would be more likely to experience worse health outcomes




The study population includes dual-eligible nursing home residents aged 65 and older living
in facilities that contracted with Omnicare as their pharmacy provider. Omnicare is the
largest LTCP provider in the U.S, serving an estimated 50 percent of nursing home residents
nationwide during the study period. For analytic purposes related to the control of
unmeasured confounders, we focus on residents randomly assigned to their PDP. In 2006,
the first year of Part D, all dual-eligible nursing home residents were randomly assigned to
an initial PDP with a premium at or below the regional benchmark; in 2007 and 2008,
residents whose PDP lost benchmark status (i.e., the plan’s premium bid for the coming year
exceeded the benchmark) were randomly reassigned to another plan. For 2007 and 2008, we
excluded individuals who elected to change PDPs in the previous year, since they would not
have been re-randomized automatically. Importantly, if residents switched plans after
randomization, their medication use and related outcomes were still assessed relative to the
initial plan to which they were randomized (i.e., an “intent-to-treat” framework). Our focus
is on residents enrolled in stand-alone PDPs.
We focus on residents taking medications on January 1st in each year in three classes:
antipsychotics, antidepressants, and cholinesterase inhibitors. We define three separate
cohorts of “current users” as those who filled at least two prescriptions in the class with 10
or more days of supply each or three prescriptions with any number of days supplied during
the 100 days before PDP randomization on January 1st of the year in question. If residents
use drugs in more than one class of interest, they could be included in more than one current
user cohort within a particular year; similarly, if they were randomized to new PDPs in more
than one year (e.g., 2006 and 2007), they may be included in more than one year. We
exclude residents who used more than one drug in the class during the 100-day period, (7%
of antipsychotic users; 17% of antidepressant users, and 1% of cholinesterase inhibitor
users), as it introduced uncertainty in defining coverage restrictiveness and current users of
particular medications.
Data
For the years 2005–2008, we link the following data for our study sample: pharmacy claims
from Omnicare, which include all claims paid by Medicare (i.e., including those covered
through Part D and those medications bundled in the Part A skilled nursing facility (SNF)
payment), Medicaid, and other payers; resident demographic traits from Medicare
Beneficiary Summary Files; assessments of residents’ health and functioning and date of
death from the Minimum Data Set (MDS); dates of hospitalization from MedPAR files; and
PDP formulary coverage and utilization requirements from the CMS Prescription Drug Plan
Formulary, Pharmacy Network and Pricing Information files. We exclude individuals who
died on January 1st of the year of randomized enrollment or who did not have at least one
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MDS assessment in the pre- and post-periods. All analyses present information on resident
current user cohorts from all three study years combined.
Explanatory variable—The key explanatory variable of interest is PDP coverage
restrictiveness, defined at the molecule – as opposed to product – level. For medications
residents were taking when they were randomized to a new plan, we code coverage
restrictiveness as a binary 0/1 variable, with 1 equaling either non-coverage or coverage
with restrictions (i.e., prior authorization or step therapy) and 0 equaling coverage without
restrictions.
Outcomes—In each class, we present information on a set of outcomes related to
medication use and health and physical functioning. Following residents’ randomization to
new plans, we track their subsequent medication use. Rather than present these usage
patterns as terminal outcomes of interest, we present information about medication changes,
gaps, stops, and continued use as mediators between PDP coverage limitations and the
cognitive, behavioral, and functional outcomes we analyze. A medication change is
indicated by a prescription claim for a drug in the same class other than the drug a resident
was taking during the 100 days before randomized enrollment. Given our focus at the
molecule level, changes between brand and generic formulations of the same drug (e.g.,
brand Paxil tablet to generic paroxetine tablet) were not considered as a “change.” A
medication gap is identified as a period of 31 or more days with no prescriptions for any
drug in the class followed by a prescription in the class within the observation window.
Medication stops are identified as no prescriptions for drugs in the class during the
observation window. Residents “continued use” if they experienced no gaps, changes, or
stops. If residents experienced more than one outcome during the observation window (e.g.,
a medication change followed by a gap), we count only the event that occurred first.
Following previous work,(4) we define the observation window as up to 30 days following
the Part D “transition period” over which CMS issued PDPs guidance to fill prescriptions
for non-covered drugs for nursing home residents while alternate therapies were considered
(up to 210 days in 2006 and 120 days in 2007 and 2008). For individuals who were
hospitalized or who died, we truncated the windows at the date of hospitalization or death.
Our primary analyses focus on the following MDS health and functional measures:
depression rating scale (0–14 scale, where 0–2 indicates no depression, 3–5 diagnosable
depression, and 6+ more severe depression)(12); presence of hallucinations or delusions in
the last seven days (yes or no); aggressive behavior scale (0–12 scale, where 1–4 indicates
mild to moderate aggressive behavior and 5+ more severe aggression)(13); cognitive
performance scale (a 0–6 scale, where 0–1 indicates no or minimal impairment, 2–4
moderate impairment, and 5–6 severe impairment)(14); and activities of daily living score
(0–28 scale, with higher scores indicating worse function).(15)
Analyses
We first present demographic and baseline health status information for the current users of
each medication class (Table 1). We present information on health and functional measures
Stevenson et al. Page 5






















at baseline, using the last MDS assessment prior to January 1st of the year of randomized
enrollment.
We next present descriptive data about PDP coverage restrictions (“any” versus “none”) and
subsequent medication use outcomes (i.e., change, gap, stop, and continued use) for
residents randomized into new PDPs (Figures 1a–1c).
Finally, we present regression results on the impact of coverage restrictions on resident
outcomes (Table 2). Using regression models, we compare outcomes measured over the
entire calendar year following randomized enrollment for dual-eligible residents to PDPs
with no coverage restrictions versus residents randomized to PDPs with some restriction.
We use linear regression for the numerical scales (depression, aggressive behavior, cognitive
performance, and activities of daily living) and present results based on the mean (across all
MDS assessments conducted during the year) scores for residents during the calendar year,
weighted by the number of assessments for an individual. We use logistic regression for the
dichotomous outcome (presence of hallucinations or delusions) and look for the presence of
this outcome at any point over the same time period. Regression models were adjusted for
the following: age (65–74, 75–84, 85–94, 95+); gender (male, female); race (black, white,
other); region (midwest, northeast, south, west); dummy variables for the drug the resident
was taking before randomization; year of randomized enrollment (2006, 2007, 2008); and
the baseline measure of the outcome of interest. We present regression coefficients to denote
the impact of PDP coverage restrictions for the MDS scales of interest (for depression,
aggressive behavior, cognitive performance, and ADLs). For hallucinations/delusions, we
present odds ratios comparing the likelihood of event occurrence. We also provide
unadjusted results in Appendix Table 2.
A concern in analyzing five outcomes across each of three medication classes is that the
chance of finding a statistically significant result when none exists is higher than the 0.05
level of a single test. We used the Bonferroni correction to account for this.(16) Using this
conservative approach to correct for our multiple tests, a p-value in any test must be less
than 0.0033 in order to report a significant finding.
Given the possibility that our results might be sensitive to modeling choices, we performed
several sensitivity analyses. In addition to combining current user groups across study years,
we examined 2006 – the transition year to Part D – separately from 2007–2008 combined. In
addition to examining the effect on health outcomes of any coverage restrictions relative to
none, we looked separately at non-coverage and utilization management requirements
relative to no coverage restrictions. In addition to using the mean score of a particular
outcome over the calendar year post randomization, we used the highest/worst assessment
observed over the same time period. We also examined the percent of residents whose status
worsened for a given outcome from baseline to the last assessment and whose assessments
placed them into the most severe categories for our outcome scales of interest (e.g., severe
depression, aggression, and cognitive impairment).
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In the three medication classes studied, study cohorts of dual-eligible nursing home residents
randomized to PDPs in 2006–2008 are comprised of 70,662 (antidepressants), 43,578
(antipsychotics), and 38,199 (cholinesterase inhibitors) residents (Table 1). Across these
classes, around three-quarters of current users are female, a similar percent are aged 75 and
above, and more than 80% are white. Baseline health status is similar for current user
groups, with some exceptions. For example, cholinesterase inhibitor users have higher levels
of hallucinations/delusions (9%) compared to antidepressant and antipsychotic users (both
around 5%). Similarly, a higher proportion of antipsychotic users have mild-moderate and
severe aggressive behaviors (36% and 6%, respectively) compared to antidepressant and
cholinesterase inhibitor users (26–28% and 3–4%, respectively).
Coverage restrictions and medication use
Figures 1a–1c show the proportion of current users facing no coverage restrictions (versus
any restrictions) in the year of randomized enrollment and medication use behaviors that
occur subsequently. For antidepressants, almost 8% of current users faced coverage
restrictions subsequent to randomization. Compared to residents who did not face such
restrictions, antidepressant users facing coverage restrictions had lower continuation rates
(58% vs. 68%, p<0.05) and significantly higher rates of changes (23% vs. 15%, p<0.05) and
gaps in use (14% vs. 12%, p<0.05) after randomized enrollment. Compared with
antidepressant users, a slightly higher proportion of antipsychotic users faced coverage
restrictions following randomization (11%), although the differences in subsequent
medication use are smaller: 64% vs. 67% (residents facing any vs. no restrictions,
respectively (p<0.05)) continued their antipsychotic; 12% vs. 10% changed antipsychotics
(p<0.05); and similar proportions had gaps in use (18% vs. 17%, not significantly different).
For cholinesterase inhibitor users, 12% faced coverage restrictions after randomization. Of
these, 60% continued to use the same cholinesterase inhibitor compared to 75% of those
who do not face restrictions (p<0.05); 7% vs. 5% change cholinesterase inhibitors (p<0.05);
and 28% vs. 15% have gaps in use (p<0.05). In all three classes, similar proportions stopped
using any drug within the class altogether, regardless of coverage restrictions.
Coverage restrictions and health outcomes
Table 2 shows the impact of Part D coverage restrictions on the clinical outcomes of nursing
home residents using antidepressants, antipsychotics, and cholinesterase inhibitors,
comparing residentsc who were randomized to PDPs with coverage restrictions for these
drugs to those who were randomized to plans with no restrictions. Across the five outcomes
examined for users in the three classes of interest, only one outcome in one drug class is
statistically significantly affected by coverage restrictions, prior to adjustment for multiple
comparisons. Cholinesterase inhibitor users randomized to a plan with any coverage
restrictions for these medications have a subsequent depression rating scale score that is 0.04
points worse (p=0.0185) compared to cholinesterase inhibitor users randomized to a plan
without any coverage restrictions (the mean baseline depression rating for these individuals
was 1.10). After correcting for multiple comparisons, this result was not statistically
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significant. All sensitivity analyses produced results consistent with these findings, i.e., no
association between coverage restrictions and outcomes.
DISCUSSION
Our findings suggest that changes to Part D plan coverage for three commonly-used
medication classes resulted in treatment disruptions but did not have a detectable impact on
outcomes for dual-eligible nursing home residents over the period 2006–2008. While we
observed a modest negative effect on depression scores for cholinesterase users, this finding
was not statistically significant after correcting for multiple comparisons. Our results are
consistent for users of antidepressants, antipsychotics, and cholinesterase inhibitors across
the common set of outcomes we examine and are robust to different modeling
specifications.
Although it is unclear why coverage restrictions had no detectable impact on resident health
outcomes, two factors stand out as potential explanations: policy protections for dual-
eligible nursing home residents generally have been effective in ensuring access to
necessary and clinically appropriate medications; or PDP coverage restrictions could have
little impact on residents’ health if suitable alternatives exist or if previously used
medications offered little clinical benefit.
Policy protections
Since Medicare Part D moved most nursing home residents from a Medicaid-financed, state-
administered drug benefit to one administered by private plans in 2006, concerns have been
raised about the potential negative impact on residents.(2) Beyond the transition’s
administrative and logistical challenges, a key focal point of concern has been that these
beneficiaries are assigned randomly to plans without regard for their medication needs. To
mitigate the potential for harmful disruptions while remaining consistent with the program’s
overall orientation toward private plans and consumer choice, a number of safeguards were
instituted, some of which are specific to the nursing home population or the dually eligible.
These include the designation of six protected classes, including two analyzed here
(antidepressants and antipsychotics).
Beyond these class-specific protections, CMS directs PDPs to cover up to a 90-day supply
of coverage limited drugs for new PDP enrollees in a nursing home, including enrollees
reassigned when their plan loses benchmark status (in 2006, the first year of our analysis,
this protection was up to 180 days). CMS also directs PDPs to cover a one-time temporary
or emergency supply (one fill or up to a 31-day supply) of non-formulary medications for
long-term care residents to lessen coverage gaps while exceptions or appeals are
adjudicated. Dual-eligible nursing home residents pay no copayments and are permitted to
change PDPs monthly, although there are concerns that relatively high levels of cognitive
impairment may affect residents’ ability to weigh plan options and complete the
administrative process to switch plans (in reality, few dual eligible beneficiaries switch plans
during the year). A final, but important stop-gap protection beyond Part D is that nursing
homes are required by statute to deliver care in accordance with residents’ clinical care
plans, even in the absence of payment from a PDP. One implication of this policy is that
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residents may be switched back to their previous drugs if problems arise in taking a new
medication.
In sum, the safeguards for nursing home residents enrolled in Part D are substantial and,
ideally, further bolstered by responsibilities of nursing home and LTCP clinical staff. Our
results provide some reassurance that these protections, individually and in combination,
were effective in minimizing the potential negative effects of coverage gaps on nursing
home residents in the initial years of Part D, at least in the classes we analyze. For example,
even though nearly 71,000 antidepressant users were randomized to a new PDP during our
study period, fewer than 10% of these residents faced coverage restrictions for these
medications, and more than half of those who did continued their medications subsequently.
Importantly, these protections can change, with CMS recently proposing a rule that would
end designation of antidepressants and antipsychotics as protected classes.(17)
Medication efficacy
The clinical impact of coverage restrictions depends on a number of factors, including
prevalence of use, available alternatives, and the efficacy of specific medications. For
instance, if a drug is seldom used because there are clinically superior alternatives, low
coverage levels may be appropriate and cause minimal burden clinically. It is possible that
we did not see an association between plan coverage and outcomes because residents did not
derive a clinical benefit from the drugs. Similarly, high levels of prior authorization might
add valuable safeguards in cases where prescribing could be questionable or potentially
harmful, either due to controversy about efficacy or concerns about risks or side effects.
Among the medication classes we analyze, antipsychotics are perhaps the best example of
this, as they represent an area where overuse has been problematic among nursing home
residents, with policymakers and clinicians working together to reduce their utilization.(18)
Moreover, studies are unclear as to whether or not cholinesterase inhibitors improve or
maintain cognitive function among nursing home residents who have moderate to advanced
cognitive impairment.(19) In contrast to clear, high-quality studies of depression in
cognitively intact elders that demonstrate efficacy of antidepressant therapy for depression,
the small number of randomized controlled studies published to date do not demonstrate
efficacy of antidepressive therapy in older adults with both depression and dementia,
potentially lessening the impact of interruptions or discontinuation of therapy.(20)
Limitations
Our study has several limitations. First, the experience of dual-eligible nursing homes
residents may not generalize to other populations in Part D (e.g., who do not have similar
policy protections) or to other medication classes. Second, we tried to select a range of
relevant health and functional outcomes that have been validated and used in the literature,
but it is possible that the outcomes were not sensitive enough to capture fully the impact of
coverage restrictions on residents’ health. Third, although MDS data have moderate to high
validity and reliability, potential inaccuracies in coding can arise due to poor medical
historical data and inter-rater variability.(21) Fourth, our analyses excluded residents using
more than one drug within a particular class; although these subgroups were small for
antipsychotic and cholinesterase inhibitor users, they accounted for 17% of antidepressant
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users. Fifth, although our data captured the impact of coverage restrictions on health in the
initial years of the Part D program, it is possible that plan utilization strategies have changed
sufficiently that their impact has become more pronounced, thus warranting further study.
Finally, given the limited number of residents who experienced medication use disruptions
due to coverage restrictions, we may have lacked adequate power to detect changes in
resident outcomes, especially in light of adjustment for multiple testing.
Conclusion
Medicare Part D produced a sea-change in the financing and administration of prescription
drugs for our nation’s elderly dual-eligible nursing home residents. Despite some residents
being randomized to plans with more restrictive coverage of their medications, we find little
detrimental impact of these changes on residents’ health and functional status in three
classes. Importantly, our findings should be interpreted in the context of the numerous Part
D safeguards for selected medication classes and for nursing home residents generally. As
the PDP marketplace continues to evolve, policymakers should remain vigilant that Part D
and its related protections continue to work well for nursing home residents and other
vulnerable Medicare beneficiaries.
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Figure 1a: Antidepressant Medication Use Behavior by Presence of Coverage Restrictions
among Dual-Eligible Nursing Home Residents, 2006–2008.
Figure 1b: Antipsychotic Medication Use Behavior by Presence of Coverage Restrictions
among Dual-Eligible Nursing Home Residents, 2006–2008.
Figure 1c: Cholinesterase Inhibitor Medication Use Behavior by Presence of Coverage
Restrictions among Dual-Eligible Nursing Home Residents, 2006–2008.
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TABLE 1
Sample Characteristics of Dual-Eligible Nursing Home Residents Using Three Medication Classes, 2006–
2008
MEDICATION CLASS (current users, 2006–2008)
Antidepressants (N=70,662) Antipsychotics (N=43,578) Cholinesterase Inhibitors (N=38,199)
Sex:
 Female 76.8% 73.2% 76.0%
 Male 23.2% 26.8% 24.0%
Age:
 65–74 18.6% 13.8% 22.7%
 75–84 40.4% 43.8% 42.3%
 85–94 36.2% 38.8% 31.3%
 95+ 4.8% 3.7% 3.7%
Race:
 White 86.5% 82.9% 83.6%
 Black 9.8% 13.6% 12.3%
 Other 3.7% 3.5% 4.1%
Outcome Measures (baseline):
Mean (SD) 1.2 (1.7) 1.4 (1.9) 1.1 (1.7)
Depression Rating Scale (0–14
score)
83.5% 80.3% 84.6%
 No depression % 13.2% 15.3% 12.4%
 Diagnosable Depression % 4.4% 3.3% 3.1%
 Severe Depression % 5.4% 4.8% 9.2%
Hallucinations or delusions during
last 7 days (0/1) % (Total)
0.7 (1.5) 1.1 (1.9) 0.8 (1.6)
Aggressive Behavior (0–12 score)
 None % 71.1% 58.3% 68.3%
 Mild to Moderate % 25.6% 35.6% 27.9%
 Severe % 3.3% 6.2% 3.8%
Cognitive Performance Scale (0–6
score)
2.8 (1.6) 3.2 (1.4) 3.2 (1.3)
 No or minimal impairment % 20.5% 12.2% 8.8%
 Moderate % 65.5% 69.2% 74.9%
 Severe % 14.0% 18.6% 16.3%
Activities of Daily Living Score (0–
28)
15.3 (8.1) 15.2 (8.2) 14.6 (8.0)
Notes: Depression Rating Scale (0–2=no depression; 3–5=diagnosable depression; 6+=more severe depression, 6+); Aggressive Behavior (1–4
score indicates mild to moderate aggressive behavior; 5+ = more severe aggression); Cognitive Performance Scale (0–1= no or minimal
impairment; 2–4=moderate impairment; 5–6=severe impairment).
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Appendix Table 1
Antidepressant, Antipsychotic, and Cholinesterase Inhibitor Medications Currently Used at the Time of
Randomized Enrollment among Dual-eligible Nursing Home Residents, 2006–2008
MEDICATION CLASS DRUG CURRENT USERS (#) CURRENT USERS (%)
Antidepressants
Amitriptyline HCl Tablet 680 0.96%
Amoxapine Tablet 7 0.01%
Bupropion HCl Sustained Release Tablet 520 0.74%
Bupropion HCl Sustained Release Tablet Xl 245 0.35%
Bupropion HCl Tablet 353 0.50%
Citalopram Hydrobromide Reformulation Solution 89 0.13%
Citalopram Hydrobromide Reformulation Tablet 17193 24.33%
Citalopram Hydrobromide Solution 53 0.08%
Citalopram Hydrobromide Tablet 5252 7.43%
Clomipramine HCl Capsule 51 0.07%
Desipramine HCl Tablet 42 0.06%
Duloxetine HCl Delayed Release Capsule 1740 2.46%
Fluoxetine HCl Delayed Release Capsule 76 0.11%
Fluoxetine HCl Solution 99 0.14%
Fluoxetine HCl Tablet 3211 4.54%
Fluvoxamine Maleate Tablet 230 0.33%
Imipramine HCl Tablet 110 0.16%
Imipramine Pamoate Capsule 1 0.00%
Maprotiline HCl Tablet 5 0.01%
Mirtazapine Dissolvable Tablet 4350 6.16%
Mirtazapine Tablet 9279 13.13%
Nefazodone HCl Tablet 26 0.04%
Nortriptyline HCl Capsule 564 0.80%
Nortriptyline HCl Solution 6 0.01%
Paroxetine HCl Reformulation Tablet 34 0.05%
Paroxetine HCl Suspension 33 0.05%
Paroxetine HCl Sustained Release Tablet 282 0.40%
Paroxetine HCl Tablet 4783 6.77%
Phenelzine Sulfate Tablet 7 0.01%
Protriptyline HCl Tablet 4 0.01%
Selegiline Patch/Disc 5 0.01%
Sertraline HCl Suspension 61 0.09%
Sertraline HCl Tablet 13177 18.65%
Tranylcypromine Sulfate Tablet 1 0.00%
Trazodone HCl Tablet 4312 6.10%
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MEDICATION CLASS DRUG CURRENT USERS (#) CURRENT USERS (%)
Trimipramine Maleate Capsule 2 0.00%
Venlafaxine HCl Continuous Delivery Caps 2792 3.95%
Venlafaxine HCl Tablet 987 1.40%
Atypical Antipsychotics
Aripiprazole Dissolvable Tablet 1 0.00%
Aripiprazole Solution 16 0.04%
Aripiprazole Tablet 1756 4.03%
Clozapine Dissolvable Tablet 18 0.04%
Clozapine Tablet 322 0.74%
Haloperidol Suspension 52 0.12%
Haloperidol Tablet 1252 2.87%
Loxapine Succinate Capsule 56 0.13%
Molindone HCl Tablet 22 0.05%
Olanzapine Dissolvable Tablet 998 2.29%
Olanzapine Tablet 10183 23.37%
Quetiapine Fumarate Sustained Release Tablet 1 0.00%
Quetiapine Fumarate Tablet 14041 32.22%
Risperidone Dissolvable Tablet 180 0.41%
Risperidone Solution 497 1.14%
Risperidone Sustained Release Tablet 7 0.02%
Risperidone Tablet 13391 30.73%
Thiothixene Capsule 100 0.23%
Ziprasidone HCl Capsule 685 1.57%
Cholinesterase Inhibitors*
Donepezil HCl Dissolvable Tablet 112 0.29%
Donepezil HCl Tablet 29196 76.43%
Galantamine Hydrobromide Solution 20 0.05%
Galantamine Hydrobromide Sustained Release 1408 3.69%
Capsule
Galantamine Hydrobromide Tablet 3326 8.71%
Rivastigmine Patch/Disc 27 0.07%
Rivastigmine Tartrate Capsule 4082 10.69%
Rivastigmine Tartrate Solution 28 0.07%
*
Namenda is a NMDA agonist and not a cholinesterase inhibitor; thus, it is not included in our analyses.
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